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Summary The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent
studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to
TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as
well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to
chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced
immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to
increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis.
Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was
used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the
clinical outcome and response to chemotherapy forthe treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of
TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those
observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from
diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because
this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their
disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic
significance of TS protein expression in primary and metastatic lesions requires further evaluation.
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There is currently considerable interest in thymidylate synthase
(TS) as a chemotherapeutic target. This enzyme catalyses the
reductive methylation of dUMP to form TMP, which, following
conversion to TTP, is incorporated into DNA. Fluorinated pyrimi-
dine inhibitors of TS, in particular 5-fluorouracil (5-FU), have
been used for many years in different drug administration sched-
ules, particularly when modulated with leucovorin (Sotos et al,
1994). More recently, novel antifolates have been developed as
specific TS inhibitors (Jackman and Calvert, 1995). TS has been
extensively studied in preclinical and clinical investigations, and it
is apparent that the sensitivity ofhuman tumour cells may be criti-
cally affected by the expression ofthis target enzyme.
The conventional evaluation of TS status in tumours has been
achieved by assessment of its catalytic activity with a tritium
release assay using [5-3H]dUMP (Spears et al, 1982) and by
assessing its binding capacity for tritiated FdUMP (Peters et al,
1991). Although not without practical problems, conventional
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methods for TS analysis have been applied to tissue samples taken
from patients on treatment (Clark et al, 1987; Swain et al, 1989;
Peters et al, 1994a, 1995). The development of antibodies to the
TS protein has provided an opportunity to develop new techniques
for measuring TS expression in both preclinical and clinical
studies. Monoclonal antibodies have been raised to electrophoreti-
cally purified TS from HeLa cells (Jastreboff et al, 1985) and to
human recombinant TS (Johnston et al, 1991). This latter reagent
has been used to develop Westem analysis, immunocytochemical
and immunohistochemical methods and enzyme-linked immuno-
sorbent assay (ELISA) systems (Johnston et al, 1993). A poly-
clonal antibody to recombinant human TS has been produced in a
rabbit and used to develop an ELISA (Aheme et al, 1992), to iden-
tify TS using immunocytochemistry in human ovarian tumour
cells obtained from malignant ascites (Freemantle et al, 1991) and
to localize TS protein in human colorectal cell lines (van der Wilt
et al, 1993) and tumours (Peters et al, 1995). More recently, cDNA
probes have been used effectively to evaluate the gene expression
ofTS (Freemantle et al, 1995; Horikoshi et al, 1992).
The role ofTS expression in determining response to TS inhibi-
tion has been addressed in many studies. Cell lines with acquired
resistance to TS inhibitors frequently show increased expression
of the enzyme (Berger et al, 1987; Johnston et al, 1992; Jackman
et al, 1995a). Also, exposure ofcells to TS inhibitors can result in
a rapid up-regulation of the enzyme both in vivo and in vitro
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(Swain et al, 1989; van der Wilt et al, 1992; Chu et al, 1993). The
relationship between intrinsic TS levels and sensitivity to TS has
also been addressed using panels of human tumour cell lines of
different origins. Although inverse relationships were observed
between TS activity and sensitivity to 5-FU (Beck et al, 1994;
Peters et al, 1994b), the correlation was relatively poor (r2 =
0.22-0.27), indicating that other factors may also be important.
The role ofTS expression in human tumours in relation to prog-
nosis and response to therapy has been addressed in several recent
studies. TS activity (mainly in metastatic lesions), as determined
by the catalytic and FdUMP-binding assays, was predictive for
response to 5-FU in 47 patients with advanced colorectal cancer.
High TS activity with poor TS inhibition correlated with no
response (Peters et al, 1994a). In a similar study on 22 tumour
biopsies, a wide range of results was obtained; high levels of TS
activity correlated with no response, but low values were found in
bothresponding andnon-responding tumours (Mulder et al, 1994).
Immunohistochemistry has been usedto determine theprognostic
importance of TS protein expression in patients with rectal cancer
(Johnston et al, 1994). These patients were in a study comparing
surgical resection alone with post-surgical adjuvant radiotherapy
or adjuvant chemotherapy [methyl-CCNU, vincristine and 5-FU
(MOF)] (Fisher et al, 1988). TS protein expression in the primary
tumour was found to be an independent prognostic marker of
disease-free survival and overall survival in this group of patients.
TS immunostaining was also significantly correlated with Dukes'
stage and adjuvant 5-FU-containing chemotherapy in Dukes' stage
B and C patients benefited those patients whose tumours had high
TS levels. In another study, both TS protein andTS gene expression
were significantly associated with response to 5-FU treatment in
patients with primary gastric tumours and in those with dissemi-
nated colorectal cancer when TS expression in metastatic lesions
was examined (Johnston et al, 1995). Initial results of an ongoing
trial have shown that TS gene expression measured by polymerase
chain reaction (PCR) in metastatic tumour is statistically associated
with resistance to therapy (Leichmann et al, 1995).
The aim of the present study was to use an immunohistochem-
ical method suitable for archival material to determine whether TS
expression in primary colorectal tumours was a prognostic marker
for response in patients undergoing subsequent (and essentially
palliative) chemotherapy for the treatment ofmetastatic disease.
MATERIALS AND METHODS
Patient population
All tumours studied were from patients treated in the Royal
Marsden Hospital GI Unit. The details of one of these studies, a
randomized trial examining the effect of interferon-alpha2b on
ambulatory infusional 5-FU, are found elsewhere (Findlay et al,
1994). An earlierrandomized clinical trial examining 750mg m-2 5
FU on days 1-5 by i.v. infusion, followed by a weekly 750 mg m-2
i.v. bolus with or without 9 million units of interferon-alpha2b s.c.
threetimes perweekwas also used (Hill etal, 1995). The third study
is a recent phase II investigation (Adenis et al, 1994) ofthe new TS
inhibitor, Tomudex (ZD 1694) (Jackman et al, 1991, 1995b).
Reagents and solutions
Chemicals were obtained from BDH unless otherwise stated.
Phosphate-buffered saliue (PBS) consisted of disodium hydrogen
orthophosphate (10.7 g), sodium dihydrogen orthophosphate (3.9
g) and sodium chloride (80 g) made up to 10 1 with deionized
water. The silver-enhanced immunogold staining kit (Amersham
International) consisted of a goat anti-rabbit antibody conjugated
to colloidal gold (Auroprobe LM) and the silver-enhancing solu-
tion (IntenSE M). Methyl green (1%) was used as a counterstain.
Normal goat serum (NGS) and bovine serum albumin (BSA) were
from Sigma. Tween 20 was used as a 0.1% solution in PBS.
Preparation ofsections
Archival tissue stored as formalin-fixed paraffin-embedded blocks
were sectioned at 3-jm-thick slices and mounted on glass slides.
Not all patients on these studies had sufficient tissue for sections
to be cut.
Several human tumourcell lines were used as controls to evaluate
the immunostaining. The human lymphoblastoid (W1L2) and the
ovarian carcinoma (CHI) cell lines were used as low TS controls,
whereas variants ofthese lines (WIL2:RzD694andCH1:RzD1694) with
acquired resistance to Tomudex (Jackman et al, 1995a) were used as
positive controls. These cell lines have been shown to have a
200-500-fold and a twofold increased level in TS expression, as
determined by several techniques including immunological analysis
(Freemantle et al, 1995; Jackman et al, 1995a) and were kindly
provided for this study by Dr A Jackman and Dr L Kelland at the
Institute ofCancerResearch. Approximately 108 cells were cultured
and washed in PBS (50 ml) and resuspended in 10% buffered
formalin for 24 h. The cells were pelleted andgently mixed with 2%
agar and left to set. The agar-suspended pellet was removed from
the Universal container, paraffin embedded and sectioned as for the
patient tissue samples. Before application of the primary antibody,
sections were prepared by dewaxing in Histoclear (National
Diagnostics) for 10 min, dehydrated in reducing concentrations of
ethanol (100% for 10 min; 90% for 5 min and 70% for 5 min),
washed in water for 10 min, then in PBS for a further 10 min.
Fresh frozen sections of tissue [CH1:Rcis human tumour
xenograft (Jones et al, 1993) and a human tumour biopsy] were
used as a comparison with formalin-fixed material. These tissues,
initially frozen in liquid nitrogen, were sectioned at 5 jm, mounted
on glass slides and stored at -20°C until required. The slides were
defrosted at 37°C for 10 min, immersed in formol calcium at 4°C
for 5 min, rinsed in acetone, first at room temperature then at
-20°C. The slides were transferred to a chloroform-acetone (1:1)
mixture at -20°C for 5 min, rinsed in -20°C acetone and in two
changes ofPBS.
TS antiserum and non-immune serum
Antibodies to human recombinant TS were produced in a New
Zealand White rabbit (R31) (Aherne et al, 1992). Both the anti-
serum and a non-immune rabbit serum were purified on a human
plasma affinity column to reduce non-specific staining on tissue
sections. The solid phase consisted of 0.5 g aminoactivated
controlled pore glass (1000 nm pore size) (a gift from Clifmar
Associates, University of Surrey, Guildford) added to 3 ml of
1.25% glutaraldehyde and mixed by rolling for 2 h. The column
was washed with 100 ml of PBS (0.05 M, pH 7.4), 0.5 ml of
normal human plasma in 1.5 ml ofPBS was added and left to mix
for 2 h. Glycine (1g) was added and mixed overnight. Following
this, the column was washed with 0.1 M glycine/HCl buffer (pH
2.0) then with PBS until the pH of the eluate returned to neutral.
The undiluted TS antiserum (lml) was allowed to drain through
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Figure 1 Immunogold staining in (A) W1L2 and (B) W1L2:RZD1694 human
lymphoblastoid cell lines with acquired resistance to Tomudex (40 x original
magnification). Slides were prepared as described in the text and stained
using the rabbit antiserum to TS
the column followed by 4 ml ofPBS. The filtered antiserum (5 ml)
represents a 1:5 dilution of the original. A rabbit non-immune
serum was treated in the same way.
Immunogold method
Following preparation of sections, excess PBS was wiped from
around the section. Primary antiserum or control antiserum,
diluted in PBS 1:50 (0.1 ml) was added to cover the section and
incubated in a humidified container overnight. The sections were
washed in PBS containing 0.1% Tween 20 (3 x 10 min), the slides
wiped and 0.1 ml of Auroprobe LM (diluted 1:40 in PBS) added
for 60 min. The slides were washed again with PBS (3 x 5min) and
water (3 x 3min) and excess fluid wiped from around the tissue
section. The IntenSE M silver enhancement solution was prepared
(2 drops of solutions A and B per slide) and applied to the sections
I . -1 U..0..1....... v..
Figure 2 TS immunogold staining (40 x original magnification) in paraffin-
embedded section of tumours with a percentage area score of (A) 4.29 and
(B) 21.2. The sections were processed as described in the text
for 17-19 min. Slides were then washed in water (2 x 5min), coun-
terstained with methyl green (5 min) and blotted dry. The sections
were dehydrated in 100% ethanol (30 s) and Histoclear (30 s), air
dried and mounted in DPX.
Image analysis
Image analysis was performed using the Microscale Transputer
Color (T425) system (Digihurst, Royston, UK), a Victor 386SX
computer and a Nikon light microscope with a Sony Red-Green-
Blue Vision Camera Module (model XC-711P). A 40 x objective
was used with a constant lamp voltage. The sample area within the
observed field was defined and had 100 x 100 pixel dimensions.
The colour thresholds were determined from sampling a control
section then applied under standard conditions to all samples. The
intensity measurements were taken from the sample area in the
field, then the slide was advanced two fields following a standard
grid pattern. The position or the sample area was only shifted from
the defined position if it fell over areas of artefact (folded tissue,
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Table 1 Patient and chemotherapy characteristics
Pretreatment data 5-FU(b) 5-FU(b) 5-FU(i) 5-FU(i) ZD1694 Total
+ IFN + IFN
Number 28 24 28 22 32 134
Median age 62 64 65 59 61 62
Gender (M:F) 19:7 17:7 12:16 16:6 20:12 84:50
Dukes' stage
A 0 0 1 0 1 2
B 5 1 4 4 3 17
C 15 16 9 7 6 53
D 8 7 14 11 22 62
Tumour differentiation
Well 3 2 0 0 0 5
Moderate 24 19 25 19 23 110
Poor 1 3 3 3 9 19
Sites of first relapse
Local 7 11 3 7 2 30
Lung 6 10 9 10 5 4
Liver 22 18 20 15 28 103
Median time to first relapse (weeks) 57 55 3 7 0 18
Response to chemotherapy
Complete 3 0 1 0 0 4
Partial 4 7 10 6 6 33
No change 17 13 14 15 22 81
Progression 3 4 1 0 3 11
Not evaluable 1 0 2 1 1 5
Median progression-free survival (months) 3.3 2.8 7.7 8.2 4.7 5.7
Median patient survival (months)
After chemotherapy 8.4 7.0 8.8 10.7 7.6 9.0
From diagnosis 25 23 22 21 25 24
refractile debris), areas of normal or no tissue or areas of stromal
tissue (which appear to stain artefactually with silver). Based on
assessment of the cumulative mean areas, a total of ten fields was
used in sample evaluation, as the means did not significantly
change when further field numbers were used. Before each sample
measurement, the field was shade corrected ensuring an evenly
distributed light intensity. Included in each batch ofsamples was a
WIL2:RZD1694 cell line positive control and a patient tumour
control. This tumour was selected because it was refractory to
Tomudex and thought likely to have high TS levels. The
percentage area score of individual tumour sections was then
expressed as a ratio to that ofthe control tumour section, enabling
comparison between batches.
Statistics
Comparisons ofthe median TS ratios in different groups was made
using the Student's t-test, while examination of response correla-
tions with the TS ratios was performed with the chi-square test.
Median time to first relapse from diagnosis and time to progres-
sion on treatment were calculated using Kaplan-Meier analysis.
RESULTS
Immunogold results
Following preliminary studies showing that the indirect alkaline
phosphatase staining method was insufficiently sensitive to
localize TS with adequate resolution above non-specific binding,
the immunogold method was evaluated. Initially, the guidelines
provided with the reagents were followed but the suggested
presoaking and dilution of antiserum in PBS containing NGS and
BSA appeared to result in high non-specific binding. Sequential
removal ofthese procedures and addition of0.1% Tween 20 to the
PBS resulted in minimal non-specific binding. Affinity purifica-
tion ofthe antiserum also minimized non-specific binding to tissue
sections and the optimum dilution for adequate positivity of the
antiserum and negative staining when the non-immune serum was
used was 1:50 (final dilution).
Using this method, the staining obtained with the antiserum was
compared with that of the non-immune serum, the antiserum
previously absorbed with TS and omission of the primary anti-
serum using the W1L2, WIL2:RzD1694, CHI and CHl:RZD1694 cell
lines and the control tumour. Both resistant lines showed greater
positivity than their respective drug-sensitive parent line. The two
fold increase in TS in the CHl:RzD1694 cell line compared with the
parent line, previously determined by the measurement of TS
activity and protein (Jackman et al, 1995b) was distinguishable
by light microscopy. As expected, the WIL2:RZD1694 staining
compared with the parent W1L2 cell line (Figure 1) gave intense
staining. However, because the cells were more widely spaced
than the cells in the patient tumour samples the percentage surface
area of staining was low. Positive immunostaining was eliminated
when sections of cells and tumour tissue were treated with non-
immune serum. No immunostaining was observed if the primary
antibody incubation was omitted. When antiserum was preab-
sorbed with TS the mean percentage area for the control tumour
section was reduced by more than 80% Figure 2 shows the
immunostaining obtained in a tumour with low (4.29% area) and
high (21.2% area) immunostaining. Frozen sections of tumour
appeared to stain less well for TS. Measurement of TS using
ELISA (Aherne et al, 1992) in the CHl:Rcis human tumour
xenograft showed that TS levels in extracts of the immediate and
delayed formalin-fixed tissue and the frozen tissue were not
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Table 2 The image analysis scores (percentage area positivity) of patients
responding to chemotherapy (CR + PR) and according to Dukes stage
TS immunostaining score (% area)
Responders (CR + PR) 9.38 ± 7.4
Non-responders (SD + PD) 8.75 ± 7.04
Dukes' stage A 2.39:4.42
Dukes' stage B 11.11 ± 9.24
Dukes' stage C 8.69 ± 6.61
Dukes' stage D 8.97 ± 7.01
significantly different. This suggested that there was poor antigen
presentation in the frozen sections.
Primary tumour results and clinical correlations
A total of 134 primary tumours from patients in one of the three
previously described studies was stained. The patient characteris-
tics and treatment outcomes are summarized in Table 1. The level
of TS staining in the tumour sections ranged between 0.29% and
32.02% area positivity (median = 7.21%). When expressed as a
ratio with the percentage area of staining of the control tumour
sample stained in the same batch, the results ranged from
0.01-5.02 (median = 0.54). The TS levels in the crypts ofadjacent
normal colonic mucosa (measured in six patients) ranged from
0.35-1.78% area staining or expressed as a ratio with the control
tumour, 0.04-0.2. This represents a tumour to normal tissue ratio
of approximately five to tenfold. Mean percentage area scores in
responders and non-responders and according to Dukes' stage are
shown in Table 2.
There was no correlation between the primary tumour TS ratio
and tumour differentiation (P = 0.6), Dukes' stage (P = 0.7) or the
presence ofmetastatic disease atdiagnosis (P = 0.5). There was no
relationship between the TS ratio and the subsequent time to
relapse following potentially curative surgery (P>0.1), nor was
there any difference in the median TS ratios ofpatients presenting
with or without metastatic tumour. Patients with local recurrences
(n = 47) had a higher median TS ratio than those who did not (0.50
vs 0.37; P = 0.076). A more statistically significant difference was
noted with patients (n = 42) who developed lung metastases vs
those who did not (0.31 vs 0.51; P = 0.025). There was no associa-
tion between median TS ratios and the development ofliver metas-
tases (P = 0.46, n = 104).
The patients' overall tumour response, using World Health
Organization criteria (Miller et al, 1981), was compared with the
TS ratio of the primary tumour. There was no difference in the TS
scores between patients who responded and those who did not,
either in individual treatment groups or in the group as a whole. By
combining the data ofthe two 5-FU±interferon studies, the impact
of both 5-FU schedule and interferon addition were investigated,
but no significant differences could be determined. In addition, the
Tomudex-treated patients showed no relationship between their
primary tumour TS ratio and response to treatment of metastatic
disease. Further analysis of the response of the whole group at
each site of disease (local, liver and lung) was performed. There
were no measurable responses in the local recurrences and TS
values were evenly distributed. The responses in liver and lung
metastases were not predicted by the TS ratio.
Time to progression on treatment for the whole group was
compared with primary tumour TS ratios divided into groups
above and below the median and no association was observed (P =
0.35). Overall patient survival from the time of diagnosis did not
correlate with the TS ratio.
DISCUSSION
The main aim of the study was to determine whether TS protein
expression in primary colorectal tumour was related to subsequent
response to treatment in patients with metastatic disease. An
immunohistochemical technique was developed for this purpose.
Initially, a method using alkaline phosphatase-labelled second
antibodies was used, but this proved too insensitive to distinguish
specific staining from non-specific staining. The immunogold
method with a greater level of sensitivity owing to its silver
enhancement step (Holgate, 1983) proved more successful, and
good differentiation between negative and positive controls was
achieved. Human tumour cell lines, which have previously been
shown to overexpress TS as determined by TS activity assays,
ELISA determinations (Jackman et al, 1995a) and gene expression
(Freemantle et al, 1995), were used during validation of the
immunohistochemical method.
Although the immunogold method was suitable for studying
achival material embedded in paraffin, further work is required to
facilitate TS antigen preservation and presentation in frozen tissue
sections.
The measurement of patient primary tumour samples with this
method revealed a wide range (>100-fold) ofTS scores (as deter-
mined by image analysis) and ratios (score compared with control
tumour). This was in spite of the fact that all the patients studied
had a poor prognosis. However, similarly wide ranges of TS
activity measurements on human tumours have been reported in
colon tumours (Peters et al, 1994a) and in tissue from patients with
head and neck cancer (Etienne et al, 1995). The median value for
TS in tumour tissue was approximately tenfold higher than that of
the normal large bowel crypt TS levels measured in those samples
with adjacent normal mucosa. Again, these results are similar to
those reported earlier in the literature on TS catalytic activity
(Sakamoto et al, 1993; Etienne et al, 1995).
As described above, comparison of the immunohistochemistry
findings with the clinical characteristics yielded few positive
results. There may be methodological reasons why the results of
this study did not show any correlations with measures of clinical
outcome. The antibodies used in this study, although prepared
against recombinant human TS, are polyclonal. However, the
substantial reduction in staining obtained when the antiserum was
preabsorbed with TS protein and the expected differential staining
obtained on a series of human tumour cell lines with different
levels ofTS activity and gene expression indicate thatthe observed
staining was specific. Image analysis, which relied on detecting
areas (pixels) ofa predetermined range ofcolour, was used to eval-
uate the staining ratherthan a subjective scoring system taking into
account the intensity and location ofstaining (Johnston et al, 1994)
and this may also have influenced the correlations. Lack ofclinical
correlation may also be affected by variation in staining between
batches of samples. However, no clinical correlations were
observed when either the actual staining score or the corrected
value (related to control tumour section included in each batch)
were used. The stability of the TS protein to the tissue-processing
steps was also considered as apossible explanation forthe negative
clinical correlations. However, using the same antibody in an
ELISA, it appeared that TS was present in approximately similar
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levels in the CH1:Rcis tumour xenograft regardless ofthe type ofor
time to fixation (data not shown).
A close correlation between TS levels in primary rectal tumours
and Dukes' stage at diagnosis has been reported (Johnston et al,
1994), but there was no such correlation in this study. This may be
explained by the fact that all of these patients, regardless of their
initial Dukes' stage, ultimately relapsed and therefore the TS levels
found may be different from those in a population of relapse-
free survivors ofsimilar stage. This probably results from the non-
standardized referral pattern for patients requiring palliative
chemotherapy in this centre. Only 14% of patients in this study
were classified at presentation as Dukes' stage A and B compared
with 42% in the previously reported study. Interestingly, in another
study, no association between TS catalytic activity and age, sex,
tumour size and site was found in a series of32 advancedcolorectal
cancers (Sanguedolce etal, 1995), and Dukes' stage A tumours had
higher TS levels than tumours from other groups, and higher
overall survival was associated with increased TS expression.
A potential indication ofthe biological association with TS and
the presenting data is that those patients with relapse in the local
site or lung had higher (but not significantly so) median tumour
levels than those who did not relapse in these sites. As the TS
scores in each ofthese groups overlapped significantly, it was not
feasible to examine levels of sensitivity and specificity for the TS
expression as a predictor ofrelapse. For this reason, based on the
population studied here, this test has no discriminatory power to
predict which patients might have benefited from local radio-
therapy, or conversely those who may not need it. This question
would be better addressed prospectively in the setting ofa surgical
adjuvant treatment study.
As discussed earlier, high TS expression has generally been
linked to resistance to TS inhibitors, and sensitivity oftumourcells
to 5-FU is associated with complete inhibition ofTS. However, in
the adjuvant setting, the benefit of chemotherapy was greater for
high TS-expressing tumours (Johnston et al, 1994), which was
explained at least in part by the lack of survival benefit in those
patients with slowly proliferating tumours, i.e. low TS-expressing
tumours. In this study, in patients with advanced disease the
inability of the TS ratio in primary tumours to predict overall
tumour and patient outcome may be caused by other factors in
addition to the nature ofthe patient population studied here.
Firstly, the TS level in the primary tumour, which is often
removed much earlier than the time chemotherapy is started, may
not reflect the TS level in metastases at various sites. It is of
interest that Johnston et al (1994) reported that, in one patient, TS
levels in a lymph node metastasis were higher than in the primary
tumour. In another study (Peters et al, 1991), 50% ofmetastatic TS
levels were higher than those in the primary tumour (7 of 14) and
lower in the other 50%. When metastatic TS levels were
measured, a close correlation with resistance to chemotherapy for
the treatment of disseminated disease was obtained (Leichman et
al, 1995). Further evaluation of TS expression in metastases (in
comparison with the primary tumour) are required.
Another potential reason that these results have been generally
negative is that, although TS-directed treatment of colorectal
cancer is the most active in the management of this disease,
tumour response rates are less than 50%. This suggests that other
pharmacological and cellular factors, e.g. dihydropyrimidine
dehydrogenase activity (Etienne et al, 1995) and p53 expression
(Zeng et al, 1994), which confer resistance to TS-directed treat-
ment, may be able to dilute out the individual impact of TS levels
in predicting response. However as TS protein expression and
activity levels are related to proliferative state (Navalgund et al,
1980; Cadman and Heimer, 1986), this protein may have a more
general role as a prognostic marker (Volm and Mattem, 1992
Suzuki et al, 1994; Volm et al, 1994) and as an indicator oftumour
response to a chemotherapeutic regime that may not necessarily
include TS-directed therapy.
In conclusion, the prognostic importance ofprimary tumour TS
protein expression, as determined by immunohistochemistry in
colorectal and other tumours, remains to be confirmed. Further
evaluation is required in retrospective and prospective studies in
which both primary and metastatic lesions are examined for TS
expression.
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